NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection

J Natl Compr Canc Netw. 2018 May;16(5S):620-623. doi: 10.6004/jnccn.2018.0036.

Abstract

Peter H. Carroll, MD, MPH, and James L. Mohler, MD, updated attendees on what is new in the 2018 NCCN Guidelines for Prostate Cancer Early Detection and for Prostate Cancer, respectively. Their presentations touched on new screening recommendations, shared decision-making, risk stratification, the role of genomic and molecular testing, active surveillance, and newer systemic treatments.

Publication types

  • Practice Guideline

MeSH terms

  • Age Factors
  • Androgen Antagonists / standards
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents, Hormonal / standards
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / urine
  • Biopsy, Large-Core Needle / standards
  • Decision Making
  • Early Detection of Cancer / methods
  • Early Detection of Cancer / standards*
  • Genetic Testing / standards
  • Humans
  • Magnetic Resonance Imaging / standards
  • Male
  • Mass Screening / methods
  • Mass Screening / standards*
  • Medical Oncology / standards
  • Middle Aged
  • Neoplasm Staging
  • Patient Selection
  • Prostate / diagnostic imaging
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Risk Assessment
  • Societies, Medical / standards
  • United States
  • Urology / standards
  • Watchful Waiting / methods
  • Watchful Waiting / standards*

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Prostate-Specific Antigen